The "tricky business" of identifying mechanisms of resistance to anti-PD-1.

<span style="margin: 0px; font-family: 'Times New Roman','serif';">Resistance to immune checkpoint inhibitors can vary between patients and amongst metastases. Understanding the genomic, transcriptomic and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them. </span>

http://ift.tt/2pZXJuk